Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity - Additional Information (Detail)

v3.2.0.727
Stockholders' Equity - Additional Information (Detail) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2015
Mar. 31, 2015
Jun. 30, 2014
Jun. 30, 2015
Jun. 30, 2014
Dec. 31, 2014
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]            
Stock-based compensation expense related to all unvested stock option $ 700,000     $ 700,000    
Employee Stock Purchase Plan to eligible employees, Number of shares purchased by employees 77,875     77,875    
Employee Stock Purchase Plan to eligible employees, Number of shares available for future sales 122,125     122,125    
Employee Stock Purchase Plan to eligible employees, compensation expense recognized $ 8,465   $ 7,128 $ 14,848 $ 15,746  
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options 14,300,000     $ 14,300,000    
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition       4 months 24 days    
Stock Issued During Period, Value, Issued for Services       $ 1,000 4,000  
Employee Benefits And Share Based Compensation $ 1,574,000   1,463,000 $ 3,395,000 2,598,000  
Chief Executive Officer [Member]            
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]            
Stock Issued During Period, Shares, Issued for Services       1,000,000    
Avenue Therapeutics, Inc. [Member]            
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]            
Weighted Market Value Percentage of Invested Capital 44.80%          
Shares Issued, Price Per Share $ 0.146     $ 0.146    
Stock Issued During Period, Value, Issued for Services $ 23,000     $ 23,000    
Employee Benefits And Share Based Compensation       $ 22,900    
Avenue Therapeutics, Inc. [Member] | Consultants [Member]            
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]            
Stock Issued During Period, Shares, Issued for Services 150,000     150,000    
Avenue Therapeutics, Inc. [Member] | Chief Executive Officer [Member]            
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]            
Stock Issued During Period, Shares, Issued for Services 1,000,000          
Avenue Therapeutics, Inc. [Member] | Share-based Compensation Award, Tranche One [Member]            
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]            
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage 50.00%          
Avenue Therapeutics, Inc. [Member] | Share-based Compensation Award, Tranche Two [Member]            
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]            
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage 12.50%          
Avenue Therapeutics, Inc. [Member] | Share-based Compensation Award, Tranche Three [Member]            
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]            
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage 50.00%          
Coronado SO Co. [Member] | Acquisition Of License [Member]            
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]            
Employee Benefits And Share Based Compensation       $ 178,500    
Mustang Bio, Inc [Member] | Acquisition Of License [Member]            
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]            
Employee Benefits And Share Based Compensation       147,000    
Checkpoint Therapeutics, Inc [Member]            
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]            
Allocated Share-based Compensation Expense $ 9,200     12,200    
Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures, Total   $ 1,500,000        
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage   25.00%        
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period   48 months        
Weighted Market Value Percentage of Invested Capital   44.80%        
Weighted Average Cost Percentage of Capital   30.00%        
Shares Issued, Price Per Share   $ 0.065        
Employee Benefits And Share Based Compensation       12,242    
Checkpoint Therapeutics, Inc [Member] | Acquisition Of License [Member]            
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]            
Employee Benefits And Share Based Compensation       $ 32,500    
Warrant [Member]            
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]            
Class of Warrant or Right, Outstanding 685,061     685,061    
Class of Warrant or Right, Exercise Price of Warrants or Rights           $ 6.65
Research and Development Expense [Member]            
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]            
Allocated Share-based Compensation Expense $ 300,000   300,000 $ 500,000 600,000  
General and Administrative Expense [Member]            
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]            
Allocated Share-based Compensation Expense $ 1,300,000   $ 1,200,000 $ 2,500,000 $ 2,000,000  
Restricted Stock [Member]            
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]            
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition       2 years 6 months    
Deferred Compensation Arrangement with Individual, Shares Issued       250,000